Obstructive hypertrophic cardiomyopathy (oHCM): cross-border specialty drug access for international patients

Quick orientation

Hypertrophic cardiomyopathy affects an estimated 1 in 500 people. Approximately two-thirds of HCM patients have obstructive physiology at some point.

Typical age of onset. Can present at any age; familial forms typically identified in young adulthood through screening.

Severity tiers. Severity ranges from minimally symptomatic to severely limiting with risk of sudden cardiac death.

Why specialty drugs for Obstructive hypertrophic cardiomyopathy (oHCM) are hard to access internationally

Camzyos (mavacamten) and Aficamten represent a new class of cardiac myosin inhibitors specifically for oHCM. Camzyos was FDA-approved in 2022; Aficamten approval is pending or recent depending on region. International registration is in early stages, and prescribing requires REMS-style monitoring in the US.

Treatments approved by the FDA

• Camzyos (mavacamten) — FDA approval: 2022. Mechanism: Selective cardiac myosin inhibitor. Route: Oral once daily. US WAC ballpark: Approximately USD 90,000 per year. Country pricing: India · Bahrain · Oman.

Cross-border pathways used for Obstructive hypertrophic cardiomyopathy (oHCM)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Personal Import Scheme

What your physician needs to know

• Confirm oHCM by echocardiography with provocation testing.
• Document NYHA class and symptom burden.
• Baseline and serial echocardiograms during titration.
• Genetic testing where familial disease is suspected.
• Cardiologist with HCM experience co-manages.

Common questions

How is Camzyos titrated?

Dose is adjusted based on serial echocardiographic measurements and clinical response.

Is it available outside the US?

Registration is rolling out. We confirm by destination.

Can I stop other heart medications?

Some patients can reduce beta-blocker or calcium channel blocker doses on Camzyos; your cardiologist decides.

How long does shipment take?

Five to ten business days from prescription receipt.

What documents are required?

Cardiologist's prescription, recent echocardiogram, NYHA class, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Obstructive hypertrophic cardiomyopathy (oHCM), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Obstructive hypertrophic cardiomyopathy (oHCM)

Reserved for you.